Summary
The document is a report titled 'Drugs to Watch 2024', which outlines emerging trends and significant developments in the pharmaceutical industry for the year 2024. It discusses new modalities and technologies that are driving medical breakthroughs, highlighting drugs and drug candidates expected to achieve important milestones. The report reviews the performance of drugs identified in the previous year, noting that 12 out of 15 flagged molecules have been approved. Specific drugs such as Bristol Myers Squibb’s SOTYKTU™ and Eisai’s LEQEMBI® are mentioned for their clinical successes. The report also addresses challenges faced by innovative medications, including Lilly’s donanemab, which encountered regulatory hurdles. Furthermore, it introduces next-generation medicines and new technology platforms, including CRISPR and AI applications, that are anticipated to transform drug discovery and development. The report is based on expert evaluations and comprehensive data sources, providing insights into the future landscape of pharmaceuticals.
